Quantitative evaluation of siRNA delivery in vivo. - Test2 - elhamkhani - TriplyDB

Quantitative evaluation of siRNA delivery in vivo.

Quantitative evaluation of siRNA delivery in vivo.

http://www.wikidata.org/entity/Q34370185

about

Nucleic acid delivery: the missing pieces of the puzzle?Ago1 Interacts with RNA polymerase II and binds to the promoters of actively transcribed genes in human cancer cells The rough endoplasmatic reticulum is a central nucleation site of siRNA-mediated RNA silencing Visualization of self-delivering hydrophobically modified siRNA cellular internalization.Phosphorylation-specific status of RNAi triggers in pharmacokinetic and biodistribution analyses siRNA carrying an (E)-vinylphosphonate moiety at the 5΄ end of the guide strand augments gene silencing by enhanced binding to human Argonaute-2.2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity.Identification of siRNA delivery enhancers by a chemical library screen.High Sensitivity RT-qPCR Assay of Nonlabeled siRNA in Small Blood Volume for Pharmacokinetic Studies: Application to Survivin siRNA.Right- and left-loop short shRNAs have distinct and unusual mechanisms of gene silencing Pharmacological Characterization of a Novel ENaCα siRNA (GSK2225745) With Potential for the Treatment of Cystic Fibrosis Technologies for investigating the physiological barriers to efficient lipid nanoparticle-siRNA delivery.Delivery of RNAi therapeutics: work in progress.Complexity in the therapeutic delivery of RNAi medicines: an analytical challenge.Delivering the promise of small ncRNA therapeutics.Enhancing siRNA delivery by employing lipid nanoparticles.Mathematical Modeling: A Tool for Optimization of Lipid Nanoparticle-Mediated Delivery of siRNA.The chemical evolution of oligonucleotide therapies of clinical utility.mRNA knockdown by single strand RNA is improved by chemical modifications Quantitative contributions of processes by which polyanion drugs reduce intracellular bioavailability and transfection efficiency of cationic siRNA lipoplex.Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates.5'-(E)-Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA-GalNAc Conjugates.

P2860

Q26851886-6AFE29BD-4B6C-49A1-9220-4EF9FE3BA5C3 Q28533855-E0043521-4DCA-4E17-8CD4-AC4ACCA03578 Q30538972-E50974B7-297B-4ABF-A8D1-46045BC094DD Q30834506-A7C71C49-EB09-429B-90C0-58DDA56FE6E7 Q33554206-423C5643-82CE-49DF-BE85-4068DB512782 Q33558210-E302C2DF-DB7F-423A-A7ED-ED628B765ED0 Q33956803-91474E07-741E-41D9-AA6A-F186A46131D0 Q35721260-DFEF5062-CEBB-4C8C-BC3F-2CBCA0D2CFC3 Q36232517-A3581D49-E2CF-4C7D-87E0-877131FEC8B4 Q36305658-69417B39-A31C-4F44-A244-ABE4D2524C00 Q36587576-4C2F5777-874D-4910-9CC1-63296CA4C730 Q38090525-B1F6CE8C-393B-49A2-B8BB-847BF45A3C31 Q38160246-76EFD960-9A77-4F79-B8F1-A4F315AFBB5A Q38221915-250A1470-66F4-4EC7-AC14-047AE0C48EA2 Q38226666-D42E9B61-8DB9-4FC8-A61A-26FB79EA43AD Q38236693-909C9AD8-6A72-48A3-B493-A3E22483735E Q38669909-49522184-96B0-4089-9734-D3B692BEE615 Q39154511-B7F064D2-4B38-4F26-8C42-9204B7845F39 Q39410779-4F684ECB-A310-4410-8CC1-191C1DD13493 Q47332775-424AAD5D-A271-4E98-8411-7E64E120A9B7 Q47363697-F039DBC1-A567-4B3A-860F-D4C51C0E29F5 Q54198182-2E0DB458-8427-463C-81DE-C95E66998C17

P2860

Quantitative evaluation of siRNA delivery in vivo.

http://www.wikidata.org/entity/Q34370185

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Quantitative evaluation of siRNA delivery in vivo.

@ast

Quantitative evaluation of siRNA delivery in vivo.

@en

Quantitative evaluation of siRNA delivery in vivo.

@nl

type

label

Quantitative evaluation of siRNA delivery in vivo.

@ast

Quantitative evaluation of siRNA delivery in vivo.

@en

Quantitative evaluation of siRNA delivery in vivo.

@nl

prefLabel

Quantitative evaluation of siRNA delivery in vivo.

@ast

Quantitative evaluation of siRNA delivery in vivo.

@en

Quantitative evaluation of siRNA delivery in vivo.

@nl

P1433

Q34370185-94070878-F7CD-4242-BB4C-0B2C7032BFF0

P1476

Q34370185-1D95CAE5-6D00-446D-B66F-6F0380728A10

P2093

Q34370185-0168D4EE-FF62-49A5-9318-6D41BFE1EB8A

Q34370185-058F5DC5-0B90-4BAA-A3B6-6F459B1C6B00

Q34370185-2923E775-931F-494B-8E18-2727A451426C

Q34370185-4B3C9EC4-60A2-4E1A-92B5-64AFDACEAE79

Q34370185-6EF3F99E-444D-4D9C-A170-C4F77A997C99

Q34370185-997FDF58-E71A-4098-AAB0-6945B83C2553

Q34370185-ADCD0DB8-B074-448D-99D3-0725D80575A7

Q34370185-B3132CEB-4730-4A12-B811-2DDCB88B58F8

Q34370185-B31B6103-2DF7-43BF-B4F6-9555BC1D6315

Q34370185-CD6FE32D-D2DC-4500-8CFA-CC92EDD8A1B7

P2860

Q34370185-0D712871-9B99-4AAC-B53A-2C7BE9D4B072

Q34370185-0EA657AA-14F0-4BFB-96A1-A3725E44C59E

Q34370185-193B6683-6734-47FD-B179-D1F8A1FF7FEA

Q34370185-215F927E-2006-4D4E-9CDA-E72548B7AC55

Q34370185-283AF3DC-0EA7-41D2-8E9E-5A4C09D08B1A

Q34370185-37A777B0-E58F-4642-9D51-42AC881D3A67

Q34370185-3AA6F238-E395-4717-8F4F-515707ED6C63

Q34370185-425C0363-76EF-480C-BEE4-015884E04CD8

Q34370185-43D342F5-5860-4241-B534-B4AD40565786

Q34370185-4E296055-7461-4608-8A51-EEAD79223634

P304

Q34370185-9D4BA330-151B-4ED3-833F-29F2CA564810

P31

Q34370185-1C9EF9E4-D93A-489E-994A-C502BDD3212E

P356

Q34370185-3824EB47-961F-4B6A-A568-E4C340AD95B2

P407

Q34370185-83E4947C-361B-4B19-8B8D-0BF76952E368

P433

Q34370185-8705B6F8-B51A-4C7A-AB38-312DADAE3810

P478

Q34370185-A4EB8D4C-AE45-452C-9FB8-564B07216BF0

P50

Q34370185-BE43A09A-24C8-47AE-84A6-435B851A571D

P577

Q34370185-5E5E341C-41F7-4577-9967-57665BC91FDA

P5875

Q34370185-0062BC55-20E4-44C1-9D3C-D5156ED6F82F

P698

Q34370185-A47EF3FA-662B-4BB3-99B2-31391321457D

P932

Q34370185-8C3756B6-0199-410A-B2F0-DBB6DF5A42CE

P356

P1433

P1476

Quantitative evaluation of siRNA delivery in vivo

@en

P2093

Alan B Sachs

http://www.w3.org/2001/XMLSchema#string

Colin J Pomerantz

http://www.w3.org/2001/XMLSchema#string

Craig Cherrin

http://www.w3.org/2001/XMLSchema#string

Hangchun Zhang

http://www.w3.org/2001/XMLSchema#string

Jessica Seitzer

http://www.w3.org/2001/XMLSchema#string

Laura Sepp-Lorenzino

http://www.w3.org/2001/XMLSchema#string

Marc T Abrams

http://www.w3.org/2001/XMLSchema#string

Martin L Koser

http://www.w3.org/2001/XMLSchema#string

Nathalie Innocent

http://www.w3.org/2001/XMLSchema#string

Nelly A Kuklin

http://www.w3.org/2001/XMLSchema#string

P2860

Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs

Importance of translation and nonnucleolytic ago proteins for on-target RNA interference

ATP-dependent human RISC assembly pathways

Real-time quantification of microRNAs by stem-loop RT-PCR

MicroRNAs: target recognition and regulatory functions

Small silencing RNAs: an expanding universe

The promises and pitfalls of RNA-interference-based therapeutics

Sequence-specific inhibition of small RNA function

Argonaute2 is the catalytic engine of mammalian RNAi

Asymmetry in the assembly of the RNAi enzyme complex

P304

2553-2563

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1261/RNA.2255810

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47403681

http://www.w3.org/2001/XMLSchema#string

P698

20940339

http://www.w3.org/2001/XMLSchema#string

P932

2995415

http://www.w3.org/2001/XMLSchema#string